All posts by: Michael Zand

Prothena Grabbing At Chunk Of $19B Immunotherapy Market: CEO Exclusive
Investor’s Business Daily
We have been working in the area of immunotherapy for a long time, so I continue to see exciting developments on the horizon for immunotherapy — in oncology and beyond. IBD: Does Prothena have any key launches or clinical trial data coming in 2017?

Troy plastic surgeon offers stem cell collection procedure
The Oakland Press
“It is very gratifying to be able to help people of all ages be prepared for future advances in medical science, and I am honored to have been selected to be the first in my profession to be trained on stem cell collection,” Schenden said in a news …
Stem Cell Research for Fighting Degenerative Disc DiseaseNews-Medical.net
Study pinpoints how skin cells’ identity can be disassembled to create stem cellsScienceBlog.com (blog)
Spinoff harnesses stem cells for new medical usesUniversity of Wisconsin-Madison
Genetic Literacy Project –Science Daily –Brantford Expositor
all 37 news articles »

‘Totipotent’ stem cells capable of forming viable embryo created from pluripotent cells
The San Diego Union-Tribune
Stem cells with characteristics of totipotency — capable of creating all the tissue types needed to build and sustain an embryo — have been created in mice by a California-led research team. Researchers found that a microRNA called miR-34a prevents …

‘Pure Genius’ finale spoilers: How will the first season end?
CarterMatt
Also, when a graffiti artist with a clotting disorder falls from a bridge, Walter, Malik and Zoe attempt to use suspended animation to stop his internal bleeding. And Walter is put in an awkward position when Julianna discovers James used the …

Dr. Borghaei on Reporting Immunotherapy-Related AEs in Lung …
OncLive
Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of …
Expert Discusses Keytruda’s Future in Lung Cancer – CureCuretoday.com

all 8 news articles »

Bristol-Myers shares slide on immunotherapy setback
Financial Times
Bristol-Myers was a pioneer of checkpoint inhibitors, a type of immunotherapy that turns the body’s immune system into a weapon against tumours — but the pharmaceuticals group shocked investors last year when its drug, Opdivo, flunked a large clinical …
Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, SadlyTheStreet.com
Bristol-Myers Dives On Opdivo Lung Cancer Setback; Merck JumpsInvestor’s Business Daily
Bristol won”t seek faster Opdivo/Yervoy lung cancer approvalNasdaq
WHBL Sheboygan –Bloomberg
all 133 news articles »

Scrambled DNA inside tumours might hinder cancer immunotherapy
Cancer Research UK
By studying large sets of genetic data the researchers at Harvard Medical School have now uncovered a potential link between how well patients respond to immunotherapy and errors in how the DNA inside their tumour cells is packaged. DNA, genetic …
Cancer Immunotherapy Market will generate new growth …Medgadget (blog)
Non-Specific Cancer Immunotherapy Drug Sales Industry – Market Outlook – Latest Development and Market TrendsSatellite PR News (press release)
Jumbled chromosomes may dampen the immune response to …Science Daily
Invest Daily News: Market Research News by Market.Biz (press release) –Military Technologies
all 14 news articles »